Skip to main content

The Therapeutic Window Problem in Antimicrobial Implant Surfaces: A Critical Review of Release-Based, Contact-Active, and Anti-Adhesive Strategies and a Dual-Endpoint Preclinical Protocol

Paper type
Critical review with an embedded preclinical evaluation protocol and invention disclosure appendix
Status
Original Work · Working Paper
Keywords:
antimicrobial coating · dental implant · biofilm · silver · antimicrobial peptide · cytocompatibility · selectivity index · peri-implant infection
Contents
  1. 1Introduction and Clinical Significance
  2. 2Critical Review of the Established Literature
  3. 3Identification of the Specific Research Gap
  4. 4Scientific Objective and Hypothesis
  5. 5Theoretical Foundation: The Elution Window
  6. 6Methodology
  7. 7Evidence Synthesis and Explicitly Labeled Theoretical Predictions
  8. 8Discussion: Mechanisms and Competing Explanations
  9. 9Implications for Implant Surgery and Restorative Dentistry
  10. 10Technical and Clinical Limitations
  11. 11Proposed Experimental and Clinical Validation
  12. 12Future Research Directions
  13. 13Evidence-Calibrated Conclusion

Abstract

Background: Biofilm on the transmucosal and exposed endosseous surfaces of dental implants initiates peri-implant disease. Many antimicrobial surface modifications have been described, most releasing metal ions or drugs, others killing on contact or resisting adhesion. Reports of antibacterial efficacy are numerous; evidence that any modification prevents peri-implant infection in humans is lacking, and antibacterial agents that reach effective concentrations may also injure the host cells on which integration depends.

Objective: To review the biological and pharmacological constraints on antimicrobial implant surfaces, to formalize the constraint imposed by cytotoxicity on release-based coatings, and to define an evaluation protocol with joint antibacterial and tissue-integration endpoints.

Methods: Critical narrative review of biofilm biology, coating classes, and systematic reviews of in vitro and in vivo studies. A first-order elution model was used to derive the maximum duration for which local concentration can exceed an inhibitory threshold without exceeding a cytotoxic threshold. A staged preclinical protocol was specified with prespecified success criteria.

Findings: Systematic reviews identify consistent in vitro antibacterial effects and a small, heterogeneous body of in vivo studies; we identified no clinical trial showing that any modification prevents peri-implant disease. The elution model shows that the protected interval cannot exceed the release time constant multiplied by the natural logarithm of the ratio of cytotoxic to inhibitory concentration, so that agents with narrow selectivity cannot protect for long however they are loaded, and every eluting coating passes through a sub-inhibitory phase. Peri-implant disease arises over years, beyond the lifetime of any finite reservoir. We hypothesize that only non-eluting contact-active or anti-adhesive surfaces can meet a dual criterion of at least a 2-log biofilm reduction after aging with non-inferior bone-to-implant contact.

Conclusions: The central difficulty is pharmacological and temporal, not a shortage of antibacterial chemistries. Coatings should be judged after aging, against multispecies biofilm, and on host-tissue endpoints at the same time. The hypothesis and model are theoretical and are presented with the experiment that could refute them.

Keywords: antimicrobial coating; dental implant; biofilm; silver; antimicrobial peptide; cytocompatibility; selectivity index; peri-implant infection

1. Introduction and Clinical Significance

Every implanted biomaterial presents a surface that host cells and bacteria can both colonize. Gristina described the outcome as a race for the surface: if tissue cells arrive first and integrate, the surface is defended; if bacteria arrive first and form a biofilm, integration is compromised and the infection resists host defenses and antibiotics [1]. Later analysis of the concept pointed out that the race does not end at implantation, because bacteria can reach a surface at any later time and because host cells that win initially must maintain their hold [2]. A dental implant is the extreme case. It passes permanently through the mucosa into an environment that carries a dense resident microbiota, and its transmucosal part is exposed to biofilm for the life of the restoration.

The clinical problem that antimicrobial surfaces are meant to solve therefore has two parts that differ in timing. Early infection, around the time of surgery, is uncommon and is addressed in practice by aseptic technique and, in many settings, antibiotic prophylaxis, which a Cochrane review found to reduce early implant failure [3]. Late infection, in the form of peri-implant mucositis and peri-implantitis, is common, plaque-associated, and develops over months to years [4, 5]. A coating that acts for days addresses the first problem; only a surface property that persists addresses the second.

Research output on antibacterial implant surfaces is very large, and reviews catalog dozens of approaches [6–8]. Translation to dental implants has been negligible. This paper asks why, and argues that the reason is structural: the requirement to harm bacteria without harming the osteoblasts, fibroblasts, and epithelial cells on which the implant depends defines a therapeutic window that many strategies cannot enter for long enough to matter.

2. Critical Review of the Established Literature

Biofilm biology relevant to coatings

Bacteria in biofilms are embedded in a matrix, grow slowly, and tolerate antimicrobial concentrations far above those that inhibit the same organisms in suspension [9, 10]. Susceptibility testing of biofilms requires dedicated methods, and the minimum biofilm eradication concentration can exceed the planktonic minimum inhibitory concentration by orders of magnitude [11]. Biofilms on implants also evade immune clearance by several mechanisms [12]. Two consequences follow for coatings. An agent must act before a mature biofilm forms, since afterward far higher concentrations are needed. And inhibition measured against planktonic single species overstates what a surface will achieve against the multispecies communities of the peri-implant sulcus, which differ between health and disease and between individuals [13].

Surface properties affect colonization independently of any antimicrobial. Rougher transmucosal surfaces accumulate more plaque in vivo, with little further benefit from smoothing below a threshold roughness of about 0.2 µm [14, 15], and reviews of material characteristics and topography conclude that roughness and surface free energy both influence biofilm formation, roughness predominating [16, 17]. Zirconia surfaces have shown lower early bacterial colonization than titanium in some in vivo comparisons [18, 19]. These effects are modest but permanent, which distinguishes them from the transient effects of released agents.

Release-based coatings

Most antimicrobial coatings are reservoirs. Silver, in ionic or nanoparticulate form, is the most studied agent: titania nanotube coatings loaded with silver nanoparticles killed planktonic bacteria and prevented adhesion for weeks in vitro [20], and silver nanoparticles embedded in titanium were reported to act through micro-galvanic effects with limited silver release [21]. Zinc-incorporated titania coatings and nanotube arrays combined antibacterial effects with enhanced osteogenic activity in vitro [22, 23]. Antibiotic-loaded nanotubes reduced bacterial adhesion while supporting osteoblast function in vitro [24]. Chlorhexidine adsorbs to saliva-coated titanium, more to rough than to smooth surfaces, and in vitro only about one percent of the adsorbed amount was released over 24 hours, which the authors interpreted as persistence at the surface [25].

The limitation of silver is its narrow selectivity. In vitro, silver nanoparticles and ions were cytotoxic to primary osteoblasts and osteoclasts at concentrations in the range needed for antibacterial effect [26]. More generally, a finite reservoir delivers a burst followed by a declining tail, and concentrations below the inhibitory level are known to select for resistant bacteria [27]; resistance to silver nanoparticles arising after repeated exposure has been demonstrated [28].

Contact-active surfaces

A second class kills without release. Surfaces bearing covalently attached cationic polymers killed bacteria on contact [29]. Antibiotics have been tethered to titanium: vancomycin-modified titanium alloy inhibited staphylococcal biofilm formation in vitro and retained activity after repeated challenges [30], and the approach has been reviewed for orthopedic implants [31]. Antimicrobial peptides have been immobilized on titanium; coatings of the peptide GL13K were reported to be stable, bactericidal against oral bacteria, and compatible with host cells in vitro [32, 33]. A systematic review of antimicrobial peptide-modified metallic implants in induced-infection animal models pooled 18 studies and found a significant antibacterial effect of the coated implants over controls, with the evidence concentrated on a few peptides and on Staphylococcus aureus [34].

A physical variant uses nanostructures alone. The nanopillars of cicada wings rupture adherent bacterial cells mechanically [35], synthetic analogs such as black silicon reproduce the effect [36], and hydrothermally grown titania nanowires on titanium were bactericidal while supporting osteogenic cells in culture [37]. Contact-active surfaces share a known weakness: a conditioning film of proteins and a layer of dead cells can mask the active surface, after which later colonizers attach unharmed.

Anti-adhesive surfaces

A third class aims to prevent attachment through hydrophilic polymer brushes, zwitterionic layers, or very smooth and low-energy finishes [7]. Their antibacterial effect is a reduction in adherent numbers, not killing. Their difficulty in an implant is that a surface that repels bacterial adhesins may also repel the proteins and cells needed for soft-tissue attachment, the quality of which depends on material and surface characteristics of the transmucosal component [38].

Multifunctional designs

Recognizing the conflict, several groups have proposed coatings that combine osteogenic and antibacterial functions [39]. The evidence is in vitro and in small animals. Reviews of the effect of dental implant surface modifications on both osseointegration and biofilm formation note that most modifications have been tested for one property or the other and rarely for both under the same conditions [40].

What systematic reviews of dental implant coatings conclude

A systematic review of antimicrobial functionalization strategies for dental implants concluded that silver-implanted, drug-loaded, peptide-bearing, polymer-coated, nanoscale, and ultraviolet-activatable surfaces all enhanced antimicrobial activity relative to commercially pure titanium, on evidence that was largely preclinical [41]. A recent systematic review confined to in vivo studies of metal coatings and physical or chemical modifications of titanium dental implant surfaces included 18 reports and interpreted them as showing reduced bacterial colonization, biofilm formation, and peri-implant inflammation [42]; the studies were heterogeneous in model and outcome, and, as far as can be judged from the published summary, none used the incidence of peri-implantitis in patients as an endpoint. A 2025 systematic review of 40 studies of antibacterial coatings for dental implants concluded that more in vitro and preclinical work is needed to assess their potential for preventing peri-implant infection [43], and a narrative review of antimicrobial and antibiofilm coatings for dental implants reported the same gap between laboratory promise and clinical evidence [44]. An earlier review of biomaterial and antibiotic strategies for peri-implantitis had already observed that local delivery systems were limited by short duration [45].

3. Identification of the Specific Research Gap

It is established that biofilm causes peri-implant disease; that many surface chemistries reduce bacterial viability or adhesion in short-term laboratory tests; that biofilm bacteria tolerate far higher concentrations than planktonic bacteria; and that some antibacterial agents are toxic to bone cells at antibacterial concentrations.

It has not been shown that any antimicrobial surface reduces peri-implant infection in humans. It is not known whether any maintains activity in the mouth beyond weeks, or whether antibacterial function can be combined with undiminished bone and soft-tissue integration in vivo.

The research methods are inadequate in four respects. Antibacterial tests are usually performed on fresh coatings against single planktonic species for 24 hours, conditions that favor release-based coatings at their burst and say nothing about performance after depletion. Cell compatibility is usually tested separately, at different times and concentrations, so that the two results cannot be combined into a judgment about the same surface state. Animal studies use endpoints of either infection or integration, seldom both. And models and outcome measures are too heterogeneous to permit quantitative synthesis across coating types [42, 43]. A conceptual gap underlies these: the field lacks a simple quantitative statement of what cytotoxicity implies for the duration of protection, and without it there is no principled way to decide which strategies are worth developing for an indication that unfolds over years.

4. Scientific Objective and Hypothesis

The objective is to determine which classes of antimicrobial implant surface can satisfy antibacterial and tissue-integration requirements simultaneously and durably.

Hypothesis H17: among antimicrobial modifications of titanium implant surfaces, only non-eluting contact-active or anti-adhesive surfaces achieve both a reduction of at least 2 log10 in viable multispecies biofilm relative to unmodified control after 28 days of aging in simulated oral fluid, and a loss of bone-to-implant contact of less than 5 percentage points relative to control at 8 weeks in a large-animal model.

H17 is falsified by any release-based coating that meets both criteria. It is also informative if no surface of any class meets both, which would indicate that the dual requirement cannot be met by surface modification alone with present technology. The 2-log criterion follows the convention used in standardized tests of antibacterial surfaces, in which antibacterial activity is expressed as a log reduction and a value of 2 is commonly taken as the threshold of effectiveness [46]; it is a convention and not a clinically validated threshold. The 5-point margin for bone-to-implant contact is a non-inferiority margin chosen to be smaller than the differences between surface types that have been regarded as biologically meaningful in animal histomorphometry [47].

5. Theoretical Foundation: The Elution Window

Efficacy measure

Antibacterial effect on a surface is expressed as the log reduction

LR = log_(10)(N_0/N) (1)

where N0 is the number of viable bacteria recovered from the control surface and N the number recovered from the test surface under the same conditions, in colony-forming units per unit area. A log reduction of 2 means that one percent of the control number survives.

First-order release

Consider a coating that releases an agent such that its concentration in the fluid layer adjacent to the surface declines exponentially from an initial value:

C(t) = C_0 e^(-k t) (2)

where C0 is the initial local concentration, k the first-order rate constant in reciprocal days, and t time in days. The half-life of release is ln 2 divided by k. Real release profiles are often biphasic or diffusion-controlled, with concentration falling as the inverse square root of time at first; the exponential is used because it gives transparent results, and the qualitative conclusions hold for any monotonic decline.

Let Cinh be the concentration required for the intended antibacterial effect, for which the minimum biofilm inhibitory concentration is the relevant quantity, and let Ctox be the concentration above which the relevant host cells are injured. Protection lasts while C(t) exceeds Cinh:

t_(eff) = 1/k ln(C_0/(C_(inh))) (3)

Loading more agent raises C0 and extends teff only logarithmically. Safety requires that C0 not exceed Ctox. The longest protected interval compatible with safety is therefore

t_(max) = 1/k ln((C_(tox))/(C_(inh))) = (ln(SI))/k (4)

where SI, the ratio of the toxic to the inhibitory concentration, is the selectivity index. Equation 4 is the central result. It states that the protected interval is the release time constant multiplied by the logarithm of the selectivity index. An agent with a selectivity index of 2 can protect for at most 0.69 time constants, which is one half-life; an index of 10 gives 2.3 time constants; an index of 100 gives 4.6. No formulation can do better without slowing release, and slowing release lowers the concentration achieved for a given load. If the selectivity index is at or below 1, as the osteoblast data suggest may be the case for silver against some organisms [26], there is no safe effective interval at all.

The sub-inhibitory tail

After teff the surface continues to release agent at concentrations below Cinh. The time spent between Cinh and one tenth of that value is

t_(sub) = (ln 10)/k (5)

which is independent of loading and equals about 3.3 half-lives. Every first-order eluting coating therefore exposes the adjacent flora to sub-inhibitory concentrations for longer than a selectivity index of 10 allows it to protect. Given that very low antibiotic concentrations select for resistance [27], this tail is a predictable cost of the release strategy and argues particularly against eluting conventional antibiotics from a permanent transmucosal device.

Temporal mismatch

Let Trisk denote the period over which infection must be prevented. For perioperative contamination Trisk is days, and a coating with a time constant of days and a selectivity index above about 10 could cover it. For peri-implantitis Trisk is the service life of the implant. No finite reservoir satisfies tmax greater than Trisk in that case. The implication is not that release-based coatings are useless, but that their rational indication in implant dentistry is the early healing period, where the baseline risk is already low and an effect would be hard to demonstrate, and that the common justification of such coatings by reference to peri-implantitis prevalence is a mismatch of time scales.

Non-eluting surfaces

A contact-active or anti-adhesive surface has no reservoir; its activity is a property of the surface and in principle persists as long as the surface is intact and accessible. Its limits are different: masking by conditioning films and debris, mechanical wear during function and hygiene, enzymatic degradation in the case of peptides, and the possibility that the property that harms bacteria also harms host cells in contact. These determine a functional lifetime that must be measured and cannot be derived from a simple equation. The contrast between the two classes is nevertheless clear: for eluting coatings durable dual success is excluded by Equation 4 unless selectivity is very high and release very slow, while for non-eluting surfaces it is an open empirical question.

Zonal requirements

The endosseous and transmucosal parts of an implant have different requirements. The endosseous surface needs osteoconduction and is exposed to bacteria only at placement or after bone loss. The transmucosal surface needs epithelial and connective tissue adhesion and is exposed to biofilm continuously. A single coating optimized for one zone is unlikely to be optimal for the other, and the evaluation protocol accordingly treats them separately.

Local concentration at the transmucosal surface

The concentration that bacteria and host cells experience is set by the balance between release and clearance and not by the amount loaded. For a transmucosal surface of area A releasing agent at flux J into a crevice flushed by crevicular fluid at volumetric flow Q, the quasi-steady concentration is

C_(ss) = (J A)/Q (6)

with J in micrograms per square millimeter per hour, A in square millimeters, and Q in microliters per hour, which gives Css in micrograms per microliter. Peri-implant crevicular fluid volume is small in health and increases with inflammation [48], so the same coating would yield a lower local concentration at an inflamed site, where antibacterial action is most needed, than at a healthy one. Release tests under sink conditions in milliliters of buffer measure J and say nothing of Css, and cytotoxicity tests in static culture wells, where released agent accumulates, expose cells to concentrations that may have no counterpart in a flowing crevice. In vitro estimates of the selectivity index may therefore be pessimistic for the transmucosal zone and realistic or optimistic for the endosseous zone, where fluid exchange is slow and a released agent can accumulate against bone. The protocol accordingly measures release in a low-volume, slow-exchange condition as well as under sink conditions and states the exchange rate used. Neither crevicular flow at implants nor the volume of the peri-implant crevice has been characterized with the precision that quantitative use of Equation 6 would require; the relation is offered as a reason for caution in extrapolating from release curves and not as a predictive tool.

6. Methodology

Review methods

The review is a critical narrative synthesis. Systematic reviews were prioritized for statements about the state of evidence on dental implant coatings, and primary reports were used for mechanisms. Evidence is identified throughout as in vitro, animal, or clinical.

Candidate surfaces

The protocol evaluates at least one representative of each class against the same unmodified control, all on the same titanium substrate and base topography: a silver-releasing coating; an antibiotic- or antiseptic-releasing coating; a covalently immobilized antimicrobial peptide or cationic layer; a nanostructured mechano-bactericidal surface; and an anti-adhesive polymer layer. Each is characterized for composition, topography, wettability, and coating thickness before testing.

Stage 1: release kinetics and selectivity

For eluting coatings, release into simulated oral fluid at 37 °C is measured at intervals over 28 days under sink conditions and under a low-volume condition approximating the peri-implant crevice, and k is estimated. Minimum inhibitory and minimum biofilm inhibitory concentrations are determined for a panel of oral species, and cytotoxic concentrations for human osteoblast-lineage cells, gingival fibroblasts, and oral keratinocytes by a metabolic assay and by a membrane-integrity assay. The selectivity index is computed for each organism and cell type, and tmax from Equation 4. A coating whose tmax is shorter than seven days for the least favorable pairing is recorded as unable to cover even the early healing period.

Stage 2: aged-coating biofilm and cell assays

All surfaces are aged by immersion in simulated oral fluid with daily exchange for 0, 7, and 28 days, with a brushing-wear cycle applied to the transmucosal specimens. After each aging interval, parallel specimens from the same batch enter two assays. In the first, specimens are conditioned with pooled human saliva and inoculated with a defined multispecies consortium, or with a saliva-derived microcosm, under flow for 72 hours; viable counts are obtained by culture and by viability-quantitative polymerase chain reaction, and biofilm architecture is examined by confocal microscopy. In the second, host cells are seeded on the specimens and attachment, viability, and differentiation markers are measured. The essential feature is that both assays are run on surfaces in the same state of aging. The Stage 2 success criteria are a log reduction of at least 2 at 28 days of aging and host-cell viability of at least 80 percent of control at day 0, when release is greatest.

Stage 3: in vivo dual endpoint

Surfaces passing Stage 2 proceed to a canine model, in which both osseointegration and plaque-induced peri-implant disease have been studied [49, 50]. Each animal receives test and control implants in randomized positions. The endosseous endpoint is bone-to-implant contact at 8 weeks in a submerged cohort, analyzed for non-inferiority with a 5-point margin. The transmucosal endpoint is assessed in a second cohort: after healing and abutment connection, plaque is allowed to accumulate for a defined period without ligatures, and bacterial load on the retrieved abutment, mucosal inflammatory infiltrate area, and marginal bone change are measured. Reporting follows ARRIVE 2.0 [51]. Systemic and local concentrations of any released agent are measured.

Table 1. Prespecified success criteria in the staged protocol.
StageAntibacterial criterionHost-tissue criterion
1tmax of at least 7 days for all organism and cell pairings (eluting coatings)Selectivity index above 1 for all pairings
2Log reduction of 2 or more against multispecies biofilm after 28 days of agingViability of 80 percent or more of control for three cell types at day 0
3Reduction in abutment bacterial load and in infiltrate area versus controlBone-to-implant contact non-inferior within 5 points; no excess soft-tissue recession

Statistical considerations

Stage 2 uses at least six independent specimens per surface, aging interval, and assay, from three coating batches, to capture batch variation. For Stage 3, the non-inferiority comparison of bone-to-implant contact with a margin of 5 points, one-sided α of 0.025, power of 0.80, and a within-animal standard deviation assumed to be 10 points requires approximately 63 paired observations by the usual formula for paired means; with several implant pairs per animal this corresponds to a study of 12 to 16 animals, and the assumption about variability must be confirmed in a pilot. The size required illustrates why claims of preserved osseointegration based on a handful of animals are not persuasive.

7. Evidence Synthesis and Explicitly Labeled Theoretical Predictions

Synthesis

Table 2 sets the coating classes against the requirements. The assessments are the authors' reading of the cited literature and are qualitative.

Table 2. Classes of antimicrobial implant surface: evidence and principal constraints.
ClassEvidence of antibacterial effectEvidence on tissue integrationPrincipal constraint
Metal-ion release (silver, zinc, copper) [20, 22, 42]Consistent in vitro; 18 in vivo reports, heterogeneousMixed; cytotoxicity of silver at antibacterial concentrations in vitro [26]Narrow selectivity; finite reservoir; resistance
Antibiotic or antiseptic release or adsorption [24, 25, 45]In vitro; duration limited by the amount loadedGenerally acceptable in vitroShort duration; sub-inhibitory tail; resistance selection [27]
Tethered antibiotics and peptides [30, 32, 34]In vitro; animal meta-analysis positive, mainly Staphylococcus aureus modelsFavorable in vitroMasking by conditioning film; stability; cost
Mechano-bactericidal nanostructures [36, 37]In vitro, mainly single speciesFavorable in vitro for some geometriesFouling; wear; efficacy against Gram-positive cocci and multispecies biofilm uncertain
Anti-adhesive layers [7]In vitro reduction of adhesionMay impair soft-tissue attachmentNo killing; durability under hygiene
Smooth or low-energy transmucosal finish [15, 16]In vivo reduction of plaque accumulation, modestCompatible with mucosal sealSmall effect size

Theoretical predictions

The following are deductions from Section 5 and have not been tested.

Prediction 1. For silver-releasing coatings, the selectivity index against oral anaerobes and human osteoblasts will be below 10 for most pairings, giving tmax of less than about 2.3 time constants, and coatings engineered for longer release will fail the cell-viability criterion at day 0 or the biofilm criterion at day 28.

Prediction 2. Log reduction for all eluting coatings will decline with aging interval, and the ranking of surfaces at day 0 will differ from the ranking at day 28. Published efficacy figures obtained on fresh coatings will overstate aged performance.

Prediction 3. Contact-active surfaces will show smaller log reductions against multispecies biofilm under salivary conditioning than against single species in buffer, by masking; whether the reduction remains above 2 is the decisive unknown for H17.

Prediction 4. In vivo, an eluting coating applied to the endosseous surface will either show reduced early bone-to-implant contact or no antibacterial effect at the time of abutment-level plaque challenge, since the reservoir will be depleted by then.

Prediction 5. A measurable anti-plaque effect in vivo will be obtained most reliably from the transmucosal finish, the property with the smallest effect size and the longest duration.

8. Discussion: Mechanisms and Competing Explanations

The argument from Equation 4 could be evaded in several ways, each of which is a research strategy.

Triggered release would decouple release from time. A coating that releases its agent only in response to bacterial enzymes, acidification, or an external stimulus does not follow first-order kinetics from the moment of placement, and its reservoir is spent only when needed. The idea is attractive and has been pursued in the general biomaterials literature [7]. It replaces the duration constraint with a capacity constraint, since the reservoir is still finite and each episode consumes part of it, and it introduces the question of whether triggers are specific enough in a site that is never sterile.

Micro-galvanic or ion-implanted silver, in which silver is embedded and little is released, is described as acting at the surface with low cytotoxicity [21]. If so it belongs with contact-active surfaces and is not constrained by Equation 4. Its durability and its efficacy against multispecies biofilm would be tested in Stage 2 like any other.

Agents with very high selectivity exist. Certain antimicrobial peptides and some conventional antibiotics have selectivity indices in the hundreds or more against susceptible organisms. For these the constraint on duration is the reservoir and the resistance cost of the sub-inhibitory tail, not toxicity. H17 as stated would be falsified by such a coating if it retained a 2-log effect at 28 days; whether a 28-day effect has clinical value for a disease that develops over years is a separate matter, addressed by the temporal argument and not by the hypothesis.

Rechargeable or replaceable reservoirs change the problem from a coating to a device. An antimicrobial carried in a component that is exchanged at maintenance visits is not limited by a single reservoir. This approach is developed as an engineering concept in the appendix; its regulatory and resistance implications are substantial.

A different objection questions the target. If peri-implantitis is driven by dysbiosis in a deepened pocket and not by colonization of a pristine surface, then a surface property matters only until bone loss begins, after which the exposed rough endosseous surface dominates. On this view the most useful antimicrobial property might be one that can be imparted to, or restored on, a contaminated surface during treatment, which is a different product from a preventive coating.

A further consideration on the host side is the mucosal seal. The epithelial and connective tissue attachment to the transmucosal component is itself a barrier to bacteria, and its quality depends on the material and surface of that component [38]. A surface that lowers bacterial numbers but weakens the attachment could increase net bacterial access to the crestal bone. None of the coating studies reviewed here measured both properties on the same specimens, which is why the in vivo stage of the protocol records soft-tissue recession and infiltrate area alongside bacterial load.

The quality of the evidence base also needs plain statement. In vitro antibacterial tests on fresh specimens are nearly universally positive, which suggests both real effects and publication bias. The small number and heterogeneity of in vivo studies [42] mean that the effect on integration is uncertain for most coatings. The analogy with orthopedic implants, from which much of the technology derives, is imperfect: orthopedic infection is predominantly a perioperative or hematogenous event at a closed site, for which a short-acting coating is rational, whereas the dental implant has a permanently open transmucosal passage.

Standardized antibacterial tests for non-porous surfaces were developed for plastics and similar products and measure activity under static, nutrient-poor conditions over 24 hours [46]. They are useful for screening and misleading as evidence of performance in the mouth.

9. Implications for Implant Surgery and Restorative Dentistry

For clinicians the implication is caution toward claims. In the literature reviewed, no antimicrobial implant surface has been shown in clinical trials to reduce peri-implant disease, and a demonstration of antibacterial activity in the laboratory is not evidence of clinical benefit. The interventions with human evidence for limiting biofilm at implants are unglamorous: smooth transmucosal surfaces, restorations that can be cleaned, and supportive care [4, 15].

For those selecting or developing products, three questions discriminate between plausible and implausible claims. Was antibacterial activity measured after aging, against multispecies biofilm? Was host-cell or tissue compatibility measured on the same surface in the same state? And does the claimed duration of action correspond to the period of clinical risk invoked to justify the product?

For antimicrobial stewardship, permanently implanted devices that elute conventional antibiotics into a colonized site at declining concentrations should be regarded with particular reserve.

10. Technical and Clinical Limitations

The elution model assumes a single exponential, a well-defined local concentration, and fixed inhibitory and toxic thresholds. In reality release is multiphasic, local concentration depends on crevicular fluid flow and tissue binding, thresholds vary with species, growth state, and exposure time, and host cells in tissue are more resilient than in monoculture. These factors alter numerical values and could widen the window in vivo relative to in vitro estimates; they do not alter the logarithmic dependence on selectivity. The 2-log and 5-point criteria are conventions. The proposed in vitro biofilm models, although multispecies, do not reproduce the host response. The canine plaque-accumulation model produces mucositis and early bone loss over months and cannot represent years of exposure, so that even a successful Stage 3 would leave long-term durability undemonstrated. The review is narrative and may have missed relevant in vivo studies, particularly outside the dental literature.

11. Proposed Experimental and Clinical Validation

The staged protocol in Section 6 is the validation plan, and its stopping rules are the criteria in Table 1. An additional bench study should precede it: verification of Equation 3 and Equation 4 for two eluting coatings of different half-life, by measuring release and time-resolved antibacterial and cytotoxic effects in the same medium, to establish how closely real coatings follow the idealized window.

Clinical evaluation would be justified only for a surface that passes Stage 3. Because peri-implantitis is slow to develop, a trial with disease incidence as the endpoint would require several hundred patients and five or more years. A more tractable first clinical study would be a randomized, split-mouth, experimental mucositis design with abutments carrying test and control transmucosal surfaces, a defined period of undisturbed plaque accumulation, and biofilm mass, composition, and crevicular inflammatory markers as outcomes, reported according to CONSORT [52]. Such a design has precedent for studying the peri-implant response to plaque and would test persistence of effect under real oral conditions in weeks, though it would not establish prevention of bone loss.

H17 is rejected if a release-based coating meets both the aged-biofilm and bone-contact criteria.

12. Future Research Directions

Useful directions are those that address duration and selectivity directly. Quantitative characterization of conditioning-film masking on contact-active surfaces would show whether their theoretical permanence is real. Methods to regenerate surface activity in situ, by light, electrical potential, or reapplication, would convert a single-use property into a maintainable one. Surfaces that modulate community composition toward health-associated taxa without killing, should such a thing be possible, would avoid selection for resistance. Zonal designs that leave the endosseous surface optimized for bone and place antimicrobial function only on retrievable transmucosal components align engineering with biology and with regulatory practicality. Finally, standard test methods specific to dental implant surfaces, incorporating aging, saliva conditioning, and multispecies biofilm, would make results comparable across laboratories.

13. Evidence-Calibrated Conclusion

Laboratory evidence that many surface modifications reduce bacterial viability or adhesion in the short term is abundant and of low directness. In vivo evidence is sparse and heterogeneous. We identified no clinical trial evidence that any antimicrobial implant surface prevents peri-implant disease. A simple pharmacokinetic argument shows that release-based coatings can protect for a period limited by the logarithm of their selectivity index and that all of them pass through a sub-inhibitory phase, and a comparison of time scales shows that such coatings cannot address a disease that arises years after placement. Whether non-eluting surfaces can maintain antibacterial activity in the mouth without impairing tissue integration is unknown and is the question most worth answering. The dual-endpoint protocol proposed here specifies what a positive answer would have to look like.

Cite this paper

Jain S, Gupta A. The Therapeutic Window Problem in Antimicrobial Implant Surfaces: A Critical Review of Release-Based, Contact-Active, and Anti-Adhesive Strategies and a Dual-Endpoint Preclinical Protocol. Working paper. Center for Implant Dentistry; 2026. Available from: https://bayareaimplantdentistry.com/clinician-research-and-publications/therapeutic-window-of-antimicrobial-implant-surfaces

References

  1. Gristina AG. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science. 1987;237(4822):1588-95. doi:10.1126/science.3629258 (opens in a new tab) PMID: 3629258 (opens in a new tab).
  2. Busscher HJ, van der Mei HC, Subbiahdoss G, Jutte PC, van den Dungen JJ, Zaat SA, et al. Biomaterial-associated infection: locating the finish line in the race for the surface. Sci Transl Med. 2012;4(153):153rv10. doi:10.1126/scitranslmed.3004528 (opens in a new tab) PMID: 23019658 (opens in a new tab).
  3. Esposito M, Grusovin MG, Worthington HV. Interventions for replacing missing teeth: antibiotics at dental implant placement to prevent complications. Cochrane Database Syst Rev. 2013;2013(7):CD004152. doi:10.1002/14651858.CD004152.pub4 (opens in a new tab) PMID: 23904048 (opens in a new tab).
  4. Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, et al. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018;89 Suppl 1:S313-S318. doi:10.1002/JPER.17-0739 (opens in a new tab) PMID: 29926955 (opens in a new tab).
  5. Derks J, Tomasi C. Peri-implant health and disease. A systematic review of current epidemiology. J Clin Periodontol. 2015;42 Suppl 16:S158-71. doi:10.1111/jcpe.12334 (opens in a new tab) PMID: 25495683 (opens in a new tab).
  6. Zhao L, Chu PK, Zhang Y, Wu Z. Antibacterial coatings on titanium implants. J Biomed Mater Res B Appl Biomater. 2009;91(1):470-80. doi:10.1002/jbm.b.31463 (opens in a new tab) PMID: 19637369 (opens in a new tab).
  7. Campoccia D, Montanaro L, Arciola CR. A review of the biomaterials technologies for infection-resistant surfaces. Biomaterials. 2013;34(34):8533-54. doi:10.1016/j.biomaterials.2013.07.089 (opens in a new tab) PMID: 23953781 (opens in a new tab).
  8. Chouirfa H, Bouloussa H, Migonney V, Falentin-Daudré C. Review of titanium surface modification techniques and coatings for antibacterial applications. Acta Biomater. 2019;83:37-54. doi:10.1016/j.actbio.2018.10.036 (opens in a new tab) PMID: 30541702 (opens in a new tab).
  9. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318-22. doi:10.1126/science.284.5418.1318 (opens in a new tab) PMID: 10334980 (opens in a new tab).
  10. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322-32. doi:10.1016/j.ijantimicag.2009.12.011 (opens in a new tab) PMID: 20149602 (opens in a new tab).
  11. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37(6):1771-6. doi:10.1128/JCM.37.6.1771-1776.1999 (opens in a new tab) PMID: 10325322 (opens in a new tab).
  12. Arciola CR, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. Nat Rev Microbiol. 2018;16(7):397-409. doi:10.1038/s41579-018-0019-y (opens in a new tab) PMID: 29720707 (opens in a new tab).
  13. Kumar PS, Mason MR, Brooker MR, O'Brien K. Pyrosequencing reveals unique microbial signatures associated with healthy and failing dental implants. J Clin Periodontol. 2012;39(5):425-33. doi:10.1111/j.1600-051X.2012.01856.x (opens in a new tab) PMID: 22417294 (opens in a new tab).
  14. Quirynen M, van der Mei HC, Bollen CM, Schotte A, Marechal M, Doornbusch GI, et al. An in vivo study of the influence of the surface roughness of implants on the microbiology of supra- and subgingival plaque. J Dent Res. 1993;72(9):1304-9. doi:10.1177/00220345930720090801 (opens in a new tab) PMID: 8395545 (opens in a new tab).
  15. Bollen CM, Papaioanno W, Van Eldere J, Schepers E, Quirynen M, van Steenberghe D. The influence of abutment surface roughness on plaque accumulation and peri-implant mucositis. Clin Oral Implants Res. 1996;7(3):201-11. doi:10.1034/j.1600-0501.1996.070302.x (opens in a new tab) PMID: 9151584 (opens in a new tab).
  16. Teughels W, Van Assche N, Sliepen I, Quirynen M. Effect of material characteristics and/or surface topography on biofilm development. Clin Oral Implants Res. 2006;17 Suppl 2:68-81. doi:10.1111/j.1600-0501.2006.01353.x (opens in a new tab) PMID: 16968383 (opens in a new tab).
  17. Subramani K, Jung RE, Molenberg A, Hammerle CH. Biofilm on dental implants: a review of the literature. Int J Oral Maxillofac Implants. 2009;24(4):616-26. PMID: 19885401 (opens in a new tab).
  18. Rimondini L, Cerroni L, Carrassi A, Torricelli P. Bacterial colonization of zirconia ceramic surfaces: an in vitro and in vivo study. Int J Oral Maxillofac Implants. 2002;17(6):793-8. PMID: 12507238 (opens in a new tab).
  19. Scarano A, Piattelli M, Caputi S, Favero GA, Piattelli A. Bacterial adhesion on commercially pure titanium and zirconium oxide disks: an in vivo human study. J Periodontol. 2004;75(2):292-6. doi:10.1902/jop.2004.75.2.292 (opens in a new tab) PMID: 15068118 (opens in a new tab).
  20. Zhao L, Wang H, Huo K, Cui L, Zhang W, Ni H, et al. Antibacterial nano-structured titania coating incorporated with silver nanoparticles. Biomaterials. 2011;32(24):5706-16. doi:10.1016/j.biomaterials.2011.04.040 (opens in a new tab) PMID: 21565401 (opens in a new tab).
  21. Cao H, Liu X, Meng F, Chu PK. Biological actions of silver nanoparticles embedded in titanium controlled by micro-galvanic effects. Biomaterials. 2011;32(3):693-705. doi:10.1016/j.biomaterials.2010.09.066 (opens in a new tab) PMID: 20970183 (opens in a new tab).
  22. Hu H, Zhang W, Qiao Y, Jiang X, Liu X, Ding C. Antibacterial activity and increased bone marrow stem cell functions of Zn-incorporated TiO2 coatings on titanium. Acta Biomater. 2012;8(2):904-15. doi:10.1016/j.actbio.2011.09.031 (opens in a new tab) PMID: 22023752 (opens in a new tab).
  23. Huo K, Zhang X, Wang H, Zhao L, Liu X, Chu PK. Osteogenic activity and antibacterial effects on titanium surfaces modified with Zn-incorporated nanotube arrays. Biomaterials. 2013;34(13):3467-78. doi:10.1016/j.biomaterials.2013.01.071 (opens in a new tab) PMID: 23439134 (opens in a new tab).
  24. Popat KC, Eltgroth M, Latempa TJ, Grimes CA, Desai TA. Decreased Staphylococcus epidermis adhesion and increased osteoblast functionality on antibiotic-loaded titania nanotubes. Biomaterials. 2007;28(32):4880-8. doi:10.1016/j.biomaterials.2007.07.037 (opens in a new tab) PMID: 17697708 (opens in a new tab).
  25. Kozlovsky A, Artzi Z, Moses O, Kamin-Belsky N, Greenstein RB. Interaction of chlorhexidine with smooth and rough types of titanium surfaces. J Periodontol. 2006;77(7):1194-200. doi:10.1902/jop.2006.050401 (opens in a new tab) PMID: 16805682 (opens in a new tab).
  26. Albers CE, Hofstetter W, Siebenrock KA, Landmann R, Klenke FM. In vitro cytotoxicity of silver nanoparticles on osteoblasts and osteoclasts at antibacterial concentrations. Nanotoxicology. 2013;7(1):30-6. doi:10.3109/17435390.2011.626538 (opens in a new tab) PMID: 22013878 (opens in a new tab).
  27. Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, Hughes D, et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog. 2011;7(7):e1002158. doi:10.1371/journal.ppat.1002158 (opens in a new tab) PMID: 21811410 (opens in a new tab).
  28. Panáček A, Kvítek L, Smékalová M, Večeřová R, Kolář M, Röderová M, et al. Bacterial resistance to silver nanoparticles and how to overcome it. Nat Nanotechnol. 2018;13(1):65-71. doi:10.1038/s41565-017-0013-y (opens in a new tab) PMID: 29203912 (opens in a new tab).
  29. Tiller JC, Liao CJ, Lewis K, Klibanov AM. Designing surfaces that kill bacteria on contact. Proc Natl Acad Sci U S A. 2001;98(11):5981-5. doi:10.1073/pnas.111143098 (opens in a new tab) PMID: 11353851 (opens in a new tab).
  30. Antoci V Jr, Adams CS, Parvizi J, Davidson HM, Composto RJ, Freeman TA, et al. The inhibition of Staphylococcus epidermidis biofilm formation by vancomycin-modified titanium alloy and implications for the treatment of periprosthetic infection. Biomaterials. 2008;29(35):4684-90. doi:10.1016/j.biomaterials.2008.08.016 (opens in a new tab) PMID: 18814909 (opens in a new tab).
  31. Hickok NJ, Shapiro IM. Immobilized antibiotics to prevent orthopaedic implant infections. Adv Drug Deliv Rev. 2012;64(12):1165-76. doi:10.1016/j.addr.2012.03.015 (opens in a new tab) PMID: 22512927 (opens in a new tab).
  32. Holmberg KV, Abdolhosseini M, Li Y, Chen X, Gorr SU, Aparicio C. Bio-inspired stable antimicrobial peptide coatings for dental applications. Acta Biomater. 2013;9(9):8224-31. doi:10.1016/j.actbio.2013.06.017 (opens in a new tab) PMID: 23791670 (opens in a new tab).
  33. Chen LY, Tee BC, Chortos AL, Schwartz G, Tse V, Lipomi DJ, et al. Continuous wireless pressure monitoring and mapping with ultra-small passive sensors for health monitoring and critical care. Nat Commun. 2014;5:5028. doi:10.1038/ncomms6028 (opens in a new tab) PMID: 25284074 (opens in a new tab).
  34. Sandhu AK, Yang Y, Li WW. In Vivo Antibacterial Efficacy of Antimicrobial Peptides Modified Metallic Implants─Systematic Review and Meta-Analysis. ACS Biomater Sci Eng. 2022;8(5):1749-1762. doi:10.1021/acsbiomaterials.1c01307 (opens in a new tab) PMID: 35412810 (opens in a new tab).
  35. Ivanova EP, Hasan J, Webb HK, Truong VK, Watson GS, Watson JA, et al. Natural bactericidal surfaces: mechanical rupture of Pseudomonas aeruginosa cells by cicada wings. Small. 2012;8(16):2489-94. doi:10.1002/smll.201200528 (opens in a new tab) PMID: 22674670 (opens in a new tab).
  36. Ivanova EP, Hasan J, Webb HK, Gervinskas G, Juodkazis S, Truong VK, et al. Bactericidal activity of black silicon. Nat Commun. 2013;4:2838. doi:10.1038/ncomms3838 (opens in a new tab) PMID: 24281410 (opens in a new tab).
  37. Tsimbouri PM, Fisher L, Holloway N, Sjostrom T, Nobbs AH, Meek RM, et al. Osteogenic and bactericidal surfaces from hydrothermal titania nanowires on titanium substrates. Sci Rep. 2016;6:36857. doi:10.1038/srep36857 (opens in a new tab) PMID: 27857168 (opens in a new tab).
  38. Rompen E, Domken O, Degidi M, Pontes AE, Piattelli A. The effect of material characteristics, of surface topography and of implant components and connections on soft tissue integration: a literature review. Clin Oral Implants Res. 2006;17 Suppl 2:55-67. doi:10.1111/j.1600-0501.2006.01367.x (opens in a new tab) PMID: 16968382 (opens in a new tab).
  39. Raphel J, Holodniy M, Goodman SB, Heilshorn SC. Multifunctional coatings to simultaneously promote osseointegration and prevent infection of orthopaedic implants. Biomaterials. 2016;84:301-314. doi:10.1016/j.biomaterials.2016.01.016 (opens in a new tab) PMID: 26851394 (opens in a new tab).
  40. Kligman S, Ren Z, Chung CH, Perillo MA, Chang YC, Koo H, et al. The Impact of Dental Implant Surface Modifications on Osseointegration and Biofilm Formation. J Clin Med. 2021;10(8). doi:10.3390/jcm10081641 (opens in a new tab) PMID: 33921531 (opens in a new tab).
  41. Grischke J, Eberhard J, Stiesch M. Antimicrobial dental implant functionalization strategies -A systematic review. Dent Mater J. 2016;35(4):545-58. doi:10.4012/dmj.2015-314 (opens in a new tab) PMID: 27477219 (opens in a new tab).
  42. Gkioka M, Rausch-Fan X. Antimicrobial Effects of Metal Coatings or Physical, Chemical Modifications of Titanium Dental Implant Surfaces for Prevention of Peri-Implantitis: A Systematic Review of In Vivo Studies. Antibiotics (Basel). 2024;13(9). doi:10.3390/antibiotics13090908 (opens in a new tab) PMID: 39335082 (opens in a new tab).
  43. Teulé-Trull M, Altuna P, Arregui M, Rodriguez-Ciurana X, Aparicio C. Antibacterial coatings for dental implants: A systematic review. Dent Mater. 2025;41(3):229-247. doi:10.1016/j.dental.2024.12.001 (opens in a new tab) PMID: 39658405 (opens in a new tab).
  44. Esteves GM, Esteves J, Resende M, Mendes L, Azevedo AS. Antimicrobial and Antibiofilm Coating of Dental Implants-Past and New Perspectives. Antibiotics (Basel). 2022;11(2). doi:10.3390/antibiotics11020235 (opens in a new tab) PMID: 35203837 (opens in a new tab).
  45. Norowski PA Jr, Bumgardner JD. Biomaterial and antibiotic strategies for peri-implantitis: a review. J Biomed Mater Res B Appl Biomater. 2009;88(2):530-43. doi:10.1002/jbm.b.31152 (opens in a new tab) PMID: 18698626 (opens in a new tab).
  46. International Organization for Standardization. ISO 22196: Measurement of antibacterial activity on plastics and other non-porous surfaces. Geneva: ISO; 2011. †
  47. Wennerberg A, Albrektsson T. Effects of titanium surface topography on bone integration: a systematic review. Clin Oral Implants Res. 2009;20 Suppl 4:172-84. doi:10.1111/j.1600-0501.2009.01775.x (opens in a new tab) PMID: 19663964 (opens in a new tab).
  48. Niimi A, Ueda M. Crevicular fluid in the osseointegrated implant sulcus: a pilot study. Int J Oral Maxillofac Implants. 1995;10(4):434-6. PMID: 7672845 (opens in a new tab).
  49. Albouy JP, Abrahamsson I, Persson LG, Berglundh T. Spontaneous progression of peri-implantitis at different types of implants. An experimental study in dogs. I: clinical and radiographic observations. Clin Oral Implants Res. 2008;19(10):997-1002. doi:10.1111/j.1600-0501.2008.01589.x (opens in a new tab) PMID: 18828815 (opens in a new tab).
  50. Carcuac O, Abrahamsson I, Albouy JP, Linder E, Larsson L, Berglundh T. Experimental periodontitis and peri-implantitis in dogs. Clin Oral Implants Res. 2013;24(4):363-71. doi:10.1111/clr.12067 (opens in a new tab) PMID: 23176551 (opens in a new tab).
  51. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410 (opens in a new tab) PMID: 32663219 (opens in a new tab).
  52. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi:10.1136/bmj.c332 (opens in a new tab) PMID: 20332509 (opens in a new tab).
  53. University of Florida Research Foundation Inc., assignee. Quaternized titanium-nitride anti-bacterial coating for dental implants. United States patent US 11,864,964 B2. 2024 Jan 9. ‡
  54. University of Florida Research Foundation Inc., assignee. Quaternized titanium-nitride anti-bacterial coating for dental implants. United States patent US 12,364,583 B2. 2025 Jul 22. ‡
  55. United States patent US 9,107,903 B2 (silver nanoparticle coating; assignee and full title to be confirmed from the USPTO record). ‡
  56. U.S. Food and Drug Administration. Principles of premarket pathways for combination products: guidance for industry and FDA staff. Silver Spring (MD): FDA; 2022. †
  57. Reference verification note. 51 of 56 references are PubMed-indexed; their bibliographic records (authors, title, journal, year, volume, pages, DOI, PMID) were retrieved programmatically from the PubMed database on November 17, 2026. ‡ Standard, regulatory record or patent whose identifying details were confirmed against the issuing body’s public record during the research phase. † Source not indexed in PubMed (book, standard, guidance or non-indexed journal); bibliographic details are cited from the published record and were not database-verified in this drafting session. Database retrieval confirms that each record exists as cited; it does not replace full-text reading by the responsible authors of every statement attributed to a source.